Evidence map›Paper›PMID 30742043›Full record

ArticleMucosal immunology2019

The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis.

Annika Wyss, Tina Raselli, Nathan Perkins, Florian Ruiz, Gérard Schmelczer, Glynis Klinke, Anja Moncsek, René Roth, Marianne R Spalinger, Larissa Hering and 11 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Mucosal immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. 25-Hydroxycholesterol in health and diseases.Journal of lipid research · 2024
    Review
  11. Implication of Oxysterols and Phytosterols in Aging and Human Diseases.Advances in experimental medicine and biology · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. CD4Frontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Annika WyssDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Tina RaselliDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Nathan PerkinsDivision of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Florian RuizLaboratories of Neuroimmunology, Division of Neurology and Neuroscience Research Center, Department of Clinical Neurosciences, Lausanne University Hospital, Epalinges, Switzerland.
Gérard SchmelczerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Glynis KlinkeDivision of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Anja MoncsekDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
René RothDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Marianne R SpalingerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Larissa HeringDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Kirstin AtrottDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Silvia LangDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Isabelle Frey-WagnerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Joachim C MertensDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Michael ScharlDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Andreas W SailerChemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Oliver PabstInstitute for Molecular Medicine, RWTH Aachen University, Aachen, Germany.
Martin HersbergerDivision of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Caroline PotLaboratories of Neuroimmunology, Division of Neurology and Neuroscience Research Center, Department of Clinical Neurosciences, Lausanne University Hospital, Epalinges, Switzerland.
Gerhard RoglerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Benjamin MisselwitzDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. benjamin.misselwitz@usz.ch.
University Hospital of Zurich · CHUniversity of Zurich · CHUniversity of Lausanne · CHNovartis Institutes for BioMedical ResearchRWTH Aachen University · DEUniversity Children's Hospital Zurich · CHUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gene encoding for Epstein-Barr virus-induced G-protein-coupled receptor 2 (EBI2) is a risk gene for inflammatory bowel disease (IBD). Together with its oxysterol ligand 7α,25-dihydroxycholesterol, EBI2 mediates migration and differentiation of immune cells. However, the role of EBI2 in the colonic immune system remains insufficiently studied. We found increased mRNA expression of EBI2 and oxysterol-synthesizing enzymes (CH25H, CYP7B1) in the inflamed colon of patients with ulcerative colitis and mice with acute or chronic dextran sulfate sodium (DSS) colitis. Accordingly, we detected elevated levels of 25-hydroxylated oxysterols, including 7α,25-dihydroxycholesterol in mice with acute colonic inflammation. Knockout of EBI2 or CH25H did not affect severity of DSS colitis; however, inflammation was decreased in male EBI2

Indexed as

AnimalsCell MovementCells, CulturedColitisColonDextran SulfateDisease Models, AnimalFemaleHumansInflammatory Bowel DiseasesMaleMiceMice, Inbred C57BLMice, KnockoutOxysterolsReceptors, G-Protein-CoupledDextran SulfateGPR183 protein, humanGpr183 protein, mouseOxysterolsReceptors, G-Protein-Coupled

Identifiers

PMID30742043
OpenAlexW2951514370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.